Home > Notice & News   
 
.    24 1/2
Subject
Hyundai Pharm, Licenses the Rights to Develop and Commercialise Cholangiocarcinoma Treatment
Content

(2015-11-09) On 9th, Hyundai announces ASLAN Pharmaceuticals licenses the rights to develop and commercialise ASLAN001 to Hyundai Pharmaceuticals in South Korea.

ASLAN Pharmaceuticals is an oncology focused biotechnology company developing immunotherapies and targeted drugs, and teamed with global pharmaceutical expertise. It is headquartered in Singapore and with regional offices in Taiwan and China, conducts clinical development programmes. The Company’s proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases.

ASLAN’s most advanced compounds are in phase 2: ASLAN001, a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma (CCA), breast cancer and gastric cancer. Hyundai will collaborate with ASLAN in development of CCA in Korean territory.

ASLAN001 is a targeted drug and a Phase 2A/B study commenced in December 2014 in second-line metastatic breast cancer across Asia. On August 2015, ASLAN001 was awarded Orphan Drug Designation by the US FDA in CCA.

Worldwide, South Korea has one of the highest prevalence rates of cholangiocarcinoma and gastric cancer, with 4,000 and 30,000 new patients diagnosed annually respectively. The cholangiocarcinoma is an aggressive form of bile duct cancer with no approved therapy and a very poor prognosis.

Under the terms of agreement, ASLAN and Hyundai will collaborate closely to accelerate the development of ASLAN001 in South Korea and will conduct clinical trials to study the efficacy of the drug in CCA. Together, both parties intend to submit an Investigational New Drug Application to the Korean Ministry of Food and Drug Safety to initiate clinical trials in Korea for CCA before the end of 2015

Hyundai also retains the first rights of negotiation to develop and commercialise ASLAN001 for gastric and breast cancer in South Korea. ASLAN will retain co-marketing rights to ASLAN001 in South Korea.Hyundai focuses in areas in CV and respiratory system, and the Company is expanding into additional areas including women’s health, CNS, and oncology. Hyundai engages in manufacturing and sales of more than 200 products in prescription medications, OTC medications, hair loss treatments, Minoxyl, bug bite treatments, Bumooly, and Korea’s first health functional beverage, Miero Fiber, etc.
Date
2015-11-09
   
 
No.
Subject
Date
2015-11-09
26
2015-10-14
24
2015-09-02
23
2015-06-25
22
2015-05-12
21
2015-04-17
20
2015-03-26
19
2014-12-12
18
2014-12-05
17
2014-11-13
16
2014-08-19
15
2014-06-30
14
2014-06-05
13
2014-03-28
12
2014-02-18